Clinical Evidence Shaping Personalized DAPT Strategies

 

 

Agenda:

  • Opening and Panel Introduction - Navid Ghaffari
  • TARGET Series Trial Overview: Building the Evidence Base for DAPT Innovation - Alexandra J. Lansky
  • Redefining Safety in Low-Risk AMI: Key highlights from TARGET-FIRST Trial - Giuseppe Tarantini
  • ULTIMATE-DAPT: One-month Ticagrelor Monotherapy After PCI in ACS - Shao-Liang Chen
  • Open Discussion: Clinical Evidence Shaping Personalized DAPT Strategies - All
  • Closing & Key Takeaway - Navid Ghaffari

Key Takeaways:

Firehawk™ Family: Next-Generation Drug-Eluting Stent (DES) powered by Target-Eluting technology

Target-Eluting Technology for Optimized Vessel Healing

  • Proprietary vessel-facing1 micro-grooves for precise drug delivery to the target lesion
  • Ultra-low drug load1 with biodegradable polymer1 confined within the micro-grooves2, designed to support rapid vessel healing3

Consistent Performance Across Diverse Patient Populations

  • Robust evidence validated in over 17,500 patients across the TARGET Series trials
  • Proven efficacy: Firehawk™ demonstrated consistent safety and efficacy performance across diverse and complex patient populations
  • Evaluated in diverse, high-risk cohorts including complex4 and high-bleeding-risk5 patient populations

Strengthening Evidence supporting Abbreviated and Personalized DAPT Strategies

  • TARGET-FIRST6, ULTIMATE DAPT7, and TARGET SAFE5 collectively supports DAPT de-escalation across a broad spectrum of patient risk profiles, ranging from low-risk AMI6 to ACS7 and high-bleeding-risk5 populations
  • Expert consensus highlights that contemporary DES performance and imaging-guided optimization enable safer tailoring of antiplatelet therapy duration.

References

  1. Data on file, MicroPort
  2. Patent CN101879102B.
  3. TARGET AC OCT Sub-study. Three-month optical coherence tomography results. EuroIntervention. 2020; DOI: 10.4244/EIJ-D-18-00226.
  4. TARGET All Comers Randomised Clinical Trial. Five-year results. EuroIntervention. 2023; DOI: 10.4244/EIJ-D-23-00409.
  5. TARGET SAFE Clinical Trial. Twelve-month results. Presented at TCT 2025. ClinicalTrials.gov Identifier: NCT03287167.
  6. TARGET-FIRST Clinical Trial. Twelve-month results. New England Journal of Medicine. DOI: 10.1056/NEJMoa2508808.
  7. ULTIMATE-DAPT Clinical Trial. Twelve-month results. The Lancet. DOI: 10.1016/S0140-6736(24)00473-2. Additional results presented at ACC 2024.

FACULTY

Shao-Liang Chen, MD, PhD  

Shao-Liang Chen, MD, PhD
Nanjing First Hospital of Nanjing Medical University
Nanjing, China

 Alexandra J. Lansky, MD  

Alexandra J. Lansky, MD
Yale School of Medicine
New Haven, CT
Giuseppe Tarantini, MD, PhD  

Giuseppe Tarantini, MD, PhD
University of Padova Medical School
Padua, Italy

    

 
 
 

 

This program was supported by:

 

 

Microport